An interventional study of therascreen® KRAS RGQ PCR Kit in Metastatic Colorectal Cancer (mCRC), sponsored by QIAGEN Gaithersburg, Inc. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-15.
Sponsored by QIAGEN Gaithersburg, Inc (part of QIAGEN) · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 388 studies in Colorectal Neoplasms with a site in United Kingdom — 72 open to participants now, 100 under way, 18 of them phase 3. Colorectal Neoplasms · United Kingdom.
Among the 388 studies in Colorectal Neoplasms with a site in United Kingdom, this one is the 62nd largest by planned enrollment of the 299 interventional ones that give a count, is one of 24 that started in 2023, is one of 64 with no phase, reaches primary completion later than 98 of the 99 other live ones, and was the 345th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →72 of the 388 studies in Colorectal Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
Dr. Chris Gaffney · Sites in United Kingdom
Ages 60–85
University of Edinburgh · Sites in United Kingdom
Ages 18+
University of Edinburgh · Sites in United Kingdom
Ages 18+ · Healthy volunteers
EMD Serono Research & Development Institute, Inc. · Sites in United Kingdom, United States, Argentina and 16 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
388 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 94 · Phase 2 119 · Phase 3 77 · Phase 4 3
First in 1993; this study’s year is marked. 24 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 150 across the 299 interventional studies, 275 across the 80 observational. Of the 235 that completed or were terminated, 83 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
193 of 388 have an industry lead sponsor. The 10 most frequent:
This study is registered under QIAGEN Gaithersburg, Inc, one of the names counted as QIAGEN. Under that name alone:
QIAGEN Gaithersburg, Inc is the lead sponsor of 27 studies on the registry; 1 is open to participants now.
QIAGEN has 2 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
24 of the studies in Colorectal Neoplasms with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04486378BioNTech SEA Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | 2026-11 |
| NCT06607458Delcath Systems Inc.Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | 2026-12 |
| NCT07151040One-carbon Therapeutics ABPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | 2026-12 |
| NCT02222844Imperial College LondonImproving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers | 2026-12 |
| NCT02246634Imperial College LondonScreening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE) | 2026-12 |
Add all 24 to your calendar (.ics) → With an account.
Among the 388 studies in Colorectal Neoplasms with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To utilize the therascreen KRAS RGQ PCR Kit, as a screening test in Amgen's Phase 3 Clinical Study Protocol 20210081, in order to identify patients with mCRC KRAS G12C mutation positive tumors to be enrolled in the drug clinical trial. Results of the Phase 3 Amgen Study 20210081 will serve as the basis for establishing the clinical performance of the therascreen® KRAS RGQ PCR Kit as a companion diagnostic (CDx) for the identification of patients with metastatic colorectal cancer, who may benefit from treatment with sotorasib.
The proposed device clinical performance study and the medicinal clinical trial will be conducted simultaneously as a combined trial according to MDCG 2022-10. The clinical trial 20210081 is a Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects with Metastatic Colorectal Cancer with KRAS p.G12C Mutation (CodeBreaK 301). It is estimated that approximately 450 patients from 31 countries will be enroled based on the presence of tumor KRAS G12C mutation, detected using therascreen KRAS RGQ PCR Kit, along with other clinical trial inclusion criteria, into the Phase III clinical trial. Results from the Phase 3 Amgen Study 20210081 will be used to evaluate the clinical performance of therascreen® KRAS RGQ PCR Kit as a CDx device for identification of patients with mCRC who may benefit from treatment with sotorasib in treatment-naïve patients with metastatic colorectal cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The therascreen® KRAS RGQ PCR Kit functions as part of this system, using the QIAamp DSP DNA FFPE Kit as a clinical sample concentrator, the Rotor-Gene Q MDx (RGQ) instrument as the platform on which PCR is performed, and KRAS specific software for PCR analysis and result reporting. The kit contains a Positive Control (PC) and a No Template Control (NTC) which are used to determine the validity of the test. The therascreen® KRAS RGQ PCR Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx (US) instrument for the detection of seven somatic mutations in the human KRAS oncogene, using DNA extracted from formalin-fixed, paraffin-embedded (FFPE), colorectal cancer (CRC) tissue
Device: therascreen® KRAS RGQ PCR Kit
The investigational device, therascreen® KRAS RGQ PCR Kit, will be used to determine the KRAS G12C mutation status of patients during the screening period of Amgen's clinical trial (20210081)
Detection of KRAS G12C mutation status
Detection of the KRAS G12C mutation status in DNA extracted from Formalin-Fixed Paraffin-Embedded (FFPE), CRC tissue using the therascreen KRAS RGQ PCR Kit to enrol approximately 450 KRAS G12C positive patients for clinical study protocol 20210081.
Time frame: 6 years; due to end 2030
Progression Free Survival (PFS)
The primary efficacy endpoint is progression free survival (PFS), defined as time from randomization until disease progression or death from any cause, whichever occur first as per the sotorasib clinical trial (Protocol 2021008).
Time frame: 6 years; due to end 2030
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Oct 2030, 82 months after the start.
Of 58 industry-sponsored interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 37. This study's planned 82 months is above that.
Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.